Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

Published:2024-09 Issue:9 Volume:25 Page:1163-1175
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Blay Jean-Yves,Devin Quentin,Duffaud Florence,Toulmonde Maud,Firmin Nelly,Collard Olivier,Bompas Emmanuelle,Verret Benjamin,Ray-Coquard Isabelle,Salas Sebastien,Henon Clemence,Honoré Charles,Brahmi Mehdi,Dufresne Armelle,Pracht Marc,Hervieu Alice,Penel Nicolas,Bertucci Francois,Rios Maria,Saada-Bouzid Esma,Soibinet Pauline,Perol David,Chabaud Sylvie,Italiano Antoine,Cesne Axel Le

Funder

European Commission

Institut National du Cancer

Publisher

Elsevier BV

Reference32 articles.

1. Gastrointestinal stromal tumours;Blay;Nat Rev Dis Primers,2021

2. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network;de Pinieux;PLoS One,2021

3. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2022

4. SELNET clinical practice guidelines for soft tissue sarcoma and GIST;Blay;Cancer Treat Rev,2022

5. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022;von Mehren;J Natl Compr Canc Netw,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imatinib in advanced GIST: if it's working, don’t stop a good thing;The Lancet Oncology;2024-09